Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Lipton, Jeffrey H  [Clear All Filters]
2024
Stavi V, Khaire N, Lipton JH, Kumar R. Haploidentical Hematopoietic Stem Cell Transplantation for Patients with Severe Aplastic Anemia-Single-Centre Experience. Curr Oncol. 2024;31(3):1246-1252.
Kantarjian HM, Jabbour EJ, Lipton JH, Castagnetti F, Brümmendorf TH. A Review of the Therapeutic Role of Bosutinib in Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2024.
Tang K, Lipton JH. Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era - forgotten but not gone. Leuk Lymphoma. 2024:1-10.
2023
Pereira MPinto, Remberger M, Chen C, Gerbitz A, Kim DDong Hwan, Kumar R, Lam W, Law ADatt, Lipton JH, Michelis FV, et al. Choosing between older matched sibling donor and younger matched unrelated donor in allogeneic hematopoietic cell transplantation: comparison of clinical outcomes in acute myeloid leukemia and myelodysplastic syndrome. Transplant Cell Ther. 2023.
Al-Shaibani E, Chen S, Chen C, Pasic I, Michelis FV, Lam W, Law A, Novitzky-Basso I, Gerbitz A, Kim DD, et al. Impact of age on hospitalization and outcomes post allogeneic hematopoietic cell transplantation outcome, a single center experience. Ann Hematol. 2023.
Moya TAlfaro, Mattsson J, Remberger M, Lipton JH, Kim DD, Viswabandya A, Kumar R, Lam W, Law AD, Gerbitz A, et al. Influence of conditioning regimen intensity on outcomes post-allogeneic hematopoietic cell transplantation for acute myeloid leukemia in complete morphological remission. Eur J Haematol. 2023.
Elebyary O, Fine N, Sun C, Saha ST, Robinson S, Mojdami ZDorna, Khoury N, Watson E, Coburn B, Lipton JH, et al. A Primed Neutrophil Subset Predicts the Risk of Bloodstream Infections in Allo-HSCT Patients: A Prospective Study. Clin Infect Dis. 2023.
Madsen K, Lee K, Chen S, Chen C, Law ADatt, Gerbitz A, Kumar R, Kim D, Lam W, Pasic I, et al. Weight loss post-allogeneic stem cell transplant is associated with increased transplant-related mortality. Support Care Cancer. 2023;31(10):564.
2022
Pérez ECamacho, Mayo S, Lipton JH, Chang E, De Souza L, Mina DSanta. Evaluation of a Group-Based Exercise and Relaxation Rehabilitation Program During Hospitalization for Allogeneic Hematopoietic Stem Cell Transplant. PM R. 2022.
2021
Novitzky-Basso I, Remberger M, Chen C, Ellison C, Pasic I, Lam W, Law A, Gerbitz A, Viswabandya A, Lipton JH, et al. Anti-thymocyte Globulin and Post-Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen-A and -B mismatched donors. Eur J Haematol. 2021.
Novitzky-Basso I, Remberger M, Chen C, Pasic I, Lam W, Law A, Gerbitz A, Viswabandya A, Lipton JH, Kim DD, et al. ATG and Post-transplant Cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts. Eur J Haematol. 2021.
Basso INovitzky, AlHayli S, Shin E, Pasic I, Al-Shaibani Z, Lam W, Law A, Michelis F, Gerbitz A, Viswabandya A, et al. Refined hepatic grading system in chronic graft-versus-host disease improves prognostic risk stratification of long-term outcomes. Eur J Haematol. 2021.
Pasic I, Alanazi W, Dranitsaris G, Lieberman L, Viswabandya A, Kim DDong Hwan, Lipton JH, Michelis FV. Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: A prospective study of feasibility, safety, and healthcare resource use. Hematol Oncol Stem Cell Ther. 2021.
2020
Alotaibi AS, Prem S, Chen S, Lipton JH, Kim DD, Viswabandya A, Kumar R, Lam W, Law AD, Mattsson J, et al. Fresh versus Frozen Allogeneic Peripheral Blood Stem Cell Grafts: a Successful Timely Option. Am J Hematol. 2020.
Alanazi W, Chen S, Lipton JH, Kim DD, Viswabandya A, Kumar R, Lam W, Law AD, Al-Shaibani Z, Mattsson J, et al. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Acta Haematol. 2020:1-8.
2019
Michelis FV, Hedley DW, Malhotra S, Chow S, Loach D, Gupta V, Kim DD, Kuruvilla J, Lipton JH, Viswabandya A, et al. Mobilization of leukemic cells using plerixafor as part of a myeloablative preparative regimen for patients with AML undergoing allografting: assessment of safety and tolerability. Biol Blood Marrow Transplant. 2019.
2018
Savoie MLynn, Bence-Bruckler I, Huebsch LB, Lalancette M, Hillis C, Walker I, Lipton JH, Forrest DL, Kim DDong Hwan. Canadian chronic myeloid leukemia outcomes post-transplant in the tyrosine kinase inhibitor era. Leuk Res. 2018;73:67-75.
2015
Hamad N, Shanavas M, Michelis FV, Uhm J, Gupta V, Seftel M, Kuruvilla J, Lipton JH, Messner HA, Kim DDong Hwan. Mycophenolate based GVHD prophylaxis is not inferior to methotrexate in myeloablative related donor stem cell transplantation. Am J Hematol. 2015.